A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00407160|
Recruitment Status : Completed
First Posted : December 4, 2006
Last Update Posted : September 7, 2011
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Official Title:||Comparison of Two Different Immunosuppression Protocols in Highly Sensitized Renal Transplant Recipients: Campath Induction With Tacrolimus Monotherapy vs Thymoglobulin Induction With Triple Drug Protocol.|
|Study Start Date :||August 2004|
|Actual Primary Completion Date :||January 2011|
|Actual Study Completion Date :||January 2011|
Patients with ESRD and high PRA who randomise to the control group. These patients will get induction therapy prior to transplant with Thymoglobulin 1.5 mg/kg/day for 4 days to a total dose of 6mg/kg.
They will receive maintenance immunosuppression with three drugs : tacrolimus, cellcept and prednisone.
Patients with ESRD and high PRA who randomise to the study group. These patients will get induction therapy prior to reperfusion of the kidney, during the transplant operation, with Campath (Alemtuzumab) 30mg, one dose. They will receive maintenance immunosuppression with tacrolimus alone (monotherapy).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00407160
|United States, Texas|
|University of Texas Medical Branch|
|Galveston, Texas, United States, 77555-0533|
|Principal Investigator:||Philip G Thomas, MD||UTMB Department of Surgery|